Core Viewpoint - Crystal Tech Holdings plans to issue zero-coupon convertible bonds totaling HKD 28.66 billion, with proceeds aimed at enhancing R&D capabilities, commercial capacity, building facilities, and supplementing working capital [1] Group 1: Bond Issuance Details - The bonds will mature in 2027 and are structured to balance financing efficiency, risk control, and the rights of both the issuer and investors [1] - The initial conversion price is set at HKD 13.85 per share, representing a premium of approximately 20% over the company's stock price of HKD 11.54 on January 7, and a premium of 31.7% over the average closing price of HKD 10.516 over the previous five trading days [1] - If fully converted, approximately 207 million new shares will be issued, accounting for 4.81% of the current issued share capital and 4.59% of the enlarged share capital, indicating a relatively moderate dilution [1] Group 2: Investor Participation and Market Response - The zero-coupon structure significantly reduces short-term financing costs for Crystal Tech Holdings, aligning with the company's current business development stage [2] - The high conversion premium reflects the company's confidence in its value and provides effective protection for existing shareholders, filtering out speculative investors [2] - The bond issuance received over 10 times subscription coverage, with participation from leading international institutions such as BlackRock, Allianz, D.E. Shaw, Amundi, and Citadel, indicating strong recognition of the company's business prospects [2] Group 3: Industry Context and Strategic Implications - Crystal Tech Holdings operates at the intersection of quantum physics, artificial intelligence, and large-scale standardized experimental robotics, covering multiple sectors including pharmaceuticals, energy, agriculture, new materials, and consumer goods [2] - The involvement of top-tier investors like BlackRock and Allianz underscores confidence in the AI and biopharmaceutical sectors, as well as recognition of the company's technological platform and commercialization potential [3] - The issuance of zero-coupon convertible bonds is expected to inject sufficient funds for R&D upgrades and commercial expansion, while also optimizing the shareholder structure and enhancing the company's influence in global capital markets [4]

Dollar traders are paying the most on record to bet on a deeper selloff in the greenback as a volatile US political landscape triggers a rush into bearish hedges. The premium for short-dated options that profit from a weaker US currency has widened to the highest level since Bloomberg began compiling the data in 2011. The bearish sentiment isn’t confined to the front-end — investors are the most pessimistic on the dollar’s long-term outlook since at least May 2025. Most Read from Bloomberg While the Bl ...

27日，Amundi首席投资官Vincent Mortier在接受彭博电视采访时指出，除了地缘政治因素，美国巨额赤字以及美联储未来政策的不确定性，也是 推动资金从美元大规模向黄金转移的关键驱动力。该公司认为，长期来看，黄金是抵御货币贬值和维持购买力的有效工具。 欧洲最大的资产管理公司Amundi表示，随着美元主导地位动摇，投资者正加速削减美元资产并转向黄金，黄金作为当前市场环境下最现实的替代 品，其价格涨势仍有延续空间。 受此避险需求和资产转移的推动，金价在周一历史上首次突破每盎司5100美元大关后，周二迎来连续第七个交易日的上涨。市场数据显示，过去 12个月内黄金价格飙升了85%，而彭博美元指数同期下跌了8.5%。 Mortier特别强调，在当前的全球汇市格局中，其他主要货币均难以构成对美元的有效替代。他直言，当前投资者"可能不想买欧元，而日元正面临 压力"，在这种背景下，黄金成为了唯一的替代选择，这一趋势在其客户的资产配置中已表现得尤为明显。 Mortier表示，目前对黄金的大部分需求来自各国央行和主权财富基金等机构投资者。他指出： "我们在过去两年半的时间里一直在配置黄金，我认为这种趋势还会继续。" 机 ...

“Bloomberg: The China Show” is your definitive source for news and analysis on the world's second-biggest economy. From politics and policy to tech and trends, David Ingles and Yvonne Man give global investors unique insight, delivering in-depth discussions with the newsmakers who matter. Chapters: 00:00:01 - Bloomberg: The China Show opens 00:03:35 - Trump threatens to hike tariffs on South Korea to 25% 00:06:30 - Amundi's Vincent Mortier on markets outlook 00:16:46 - What to watch in greater China today 0 ...

RT Ethereum (@ethereum)Ethereum is the #1 choice for global financial institutions.Over the last few months, adoption has accelerated. Here are 35 stories of how institutions are building on Ethereum.1/ @krakenfx launched xStocks on Ethereum, issuing tokenized versions of popular U.S. stocks and ETFs as ERC-20 tokens.Kraken’s eligible clients can now deposit and withdraw fully collateralized equities, directly on Ethereum.2/ @OndoFinance launched Ondo Global Markets on Ethereum with 100+ tokenized U.S. stoc ...

Core Viewpoint - SBI Mutual Fund is planning a significant IPO in 2026, aiming to raise over $1 billion and potentially becoming one of India's largest IPOs in recent years [1][3]. Group 1: IPO Details - The IPO will involve a combined 10% stake divestment by the State Bank of India (SBI) and its joint-venture partner Amundi, with SBI selling approximately 6.3% and Amundi offloading around 3.7% [1]. - The IPO could value SBI Funds Management at around $14 billion, although this valuation is not yet confirmed [3]. Group 2: Advisory and Management - A consortium of major investment banks has been appointed to manage the transaction, including Kotak Mahindra Capital, Axis Capital, SBI Capital Markets, Motilal Oswal, ICICI Securities, JM Financial, and the Indian units of Citigroup, HSBC, and Bank of America [2]. - These advisors are expected to finalize plans ahead of the proposed 2026 listing [2]. Group 3: Market Impact - If successful, this IPO will be the third major SBI subsidiary to be publicly listed, following SBI Cards and SBI Life Insurance, providing investment opportunities for both retail and institutional investors [3].

French asset management company Amundi has unveiled a set of senior management appointments spanning its real assets and distribution activities. The asset manager said that all changes took effect on 1 January 2026. Under the changes, Alexandre Lefebvre has been appointed deputy head of the group’s real and alternative assets division. Pierre-Adrien Domon will take over as CEO of Sabadell Asset Management, while Michaël Martineau has been named CEO of Fund Channel. In addition, Claire Chabrier has be ...

Core Insights - Ethereum has made significant progress in gaining acceptance among centralized institutions in 2025, a year marked by major regulatory changes in the crypto industry [2][3] - The network's builders have historically focused on technical achievements and decentralization, but this year has seen a shift towards broader economic and political engagement [1][2] Group 1: Institutional Adoption - Centralized institutions are urgently expanding their businesses onto blockchain networks, with a notable preference for Ethereum's multi-layer network model [5][6] - Major financial players, including Fidelity and SWIFT, have chosen Ethereum for their tokenization projects, indicating a strong institutional validation of the network [6][7] - The trend of adopting Ethereum has occurred organically, driven by its perceived suitability for business rather than through aggressive marketing efforts [5][6] Group 2: Global Reach - Financial institutions from various regions, including Upbit in South Korea, Ant Group in China, and Amundi in Europe, have engaged in tokenization projects using Ethereum [7] - The success of Ethereum in institutional settings is exemplified by the establishment of layer-2 networks, such as Base, which have gained traction in Wall Street circles [6][7]

Core Insights - Moderna, Inc. (NASDAQ: MRNA) is recognized for its mRNA technology, which was pivotal in the development of COVID-19 vaccines, and competes with major pharmaceutical companies like Pfizer and BioNTech [1] - Jefferies has set a price target of $30 for Moderna, indicating a modest potential increase of 1.28% from its current price of $29.62 [1][5] Investment Activity - Amundi has reduced its stake in Moderna by 31.9%, selling 425,861 shares, leaving it with 909,429 shares valued at $27.5 million, which is about 0.23% of Moderna [2] - In contrast, Natixis Advisors LLC increased its stake by 70.7%, now holding 17,761 shares valued at $504,000 [2] - Charles Schwab Investment Management Inc. expanded its position in Moderna by 12.2%, owning 2,629,865 shares worth $74.6 million [3] Stock Performance - Despite the varying investment strategies, Moderna's stock price has seen a 2.03% increase, reaching $29.62 [3][5] - The stock has fluctuated between $28.87 and $29.66 today, with a 52-week high of $48.92 and a low of $22.28 [4] - Moderna's market capitalization is approximately $11.57 billion, with a trading volume of 7,159,436 shares on the NASDAQ exchange [4][5]

Core Viewpoint - Moderna, Inc. has been a focal point in the biotechnology sector, particularly due to its mRNA-based vaccine developments, and recent investment activities indicate mixed sentiment among institutional investors [1][2][3][4][5] Investment Activity - Amundi has reduced its stake in Moderna by 31.9%, selling 425,861 shares, which leaves it with 909,429 shares valued at $27.5 million, indicating a strategic shift [2] - Conversely, Natixis Advisors LLC increased its stake by 70.7%, now holding 17,761 shares valued at $504,000, while Charles Schwab Investment Management Inc. raised its holdings by 12.2%, owning 2,629,865 shares worth $74.6 million [3][5] Stock Performance - Moderna's stock price is currently at $29.62, reflecting a 2.03% increase, with fluctuations between $28.87 and $29.66 on the day [4] - Over the past year, the stock reached a high of $48.92 and a low of $22.28, showcasing significant volatility [4] - The company's market capitalization stands at approximately $11.57 billion, with a trading volume of 7,159,436 shares on the NASDAQ exchange, indicating active investor interest [4]